Pulmonary arterial hypertension (PAH) is a rare condition where blood has difficulty flowing from the heart to the lungs, resulting in fatigue, shortness of breath, chest pain, and heart failure. PAH is frequently seen in women between the ages of 30 and 60, affecting African American and Hispanic women the most.
Currently no treatment exists for PAH. The condition can develop on its own or be linked to other diseases. Management of the condition can improve life expectancy.
The American Lung Association estimates that between 500 and 1000 Americans are diagnosed with PAH every year. Diagnosis can be difficult because the symptoms of PAH are similar to many other conditions.
The following is a non-exhaustive, real time rundown of PAH from the past few years and into a few months ahead. We will look at the release of guidelines, recently completed and pending clinical trials, notable journal articles, and FDA-approved medications indicated for the treatment of PAH.
Pulmonary Arterial Hypertension in Real Time
- September 2025
- Clinical Trial anticipated completion: Efficacy and Safety of Seralutinib in Adult Subjects with PAH (PROSERA), GB002, Inc.
- May 2025
- Clinical Trial completion: Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil, Liquidia Technologies, Inc.
- April 2025
- Clinical Trial completion: Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)(HYPERION), Acceleron Pharma, Inc.
- October 2024
- Journal Article: Treatment Algorithm for Pulmonary Arterial Hypertension, The European Respiratory Journal
- September 2023
- Journal Article: Treatment of Pulmonary Arterial Hypertension: Recent Progress and a Look to the Future, The Lancet/Respiratory Medicine
- October 2022
- Guidelines: Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension, European Society of Cardiology/European Respiratory Society/International Society for Heart and Lung Transplantation/European Reference Network on Rare Respiratory Diseases
- April 2022
- Journal Article: Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review, Journal of the American Medical Association
- August 2020
- Guidelines: Guidelines for the Treatment of Pulmonary Arterial Hypertension, Lung
- March 2019
- Guidelines: Therapy for Pulmonary Arterial Hypertension in Adults, American College of Chest Physicians
- December 2015
- Approval: FDA approved Uptravi (selexipag) for the treatment of PAH.
- December 2013
- Approval: FDA approved Orenitram (treprostnil) for the treatment of PAH.
- May 2009
- Approval: FDA approved Adcirca (tadalafil) for the treatment of PAH.
- June 2005
- Approval: FDA Approved Revatio (sildenafil citrate) for the treatment of PAH.
Sign up for alerts to keep up with the latest guidelines and insights.
Copyright © 2025 Guideline Central, all rights reserved.